AI assistant
IO Biotech, Inc. — Director's Dealing 2023
Aug 12, 2023
34883_dirs_2023-08-11_4f8e44f4-ec0d-4fd4-8a11-83d24138050b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IO Biotech, Inc. (IOBT)
CIK: 0001865494
Period of Report: 2023-08-09
Reporting Person: Elling Christian E (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-08-09 | Common Stock | A | 7901234 | $1.9 | Acquired | 13950686 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-08-09 | Warrants (Right to Buy) | $2.47 | A | 7901234 | Acquired | Common Stock (7901234) | Indirect |
Footnotes
F1: The securities are held of record by Lundbeckfond Invest A/S. The Reporting Person is Managing Partner of Lundbeckfonden Emerge, a division of Lundbeckfond Invest A/S. The Reporting Person disclaims beneficial ownership of the securities held by Lundbeckfond Invest A/S except to the extent of his pecuniary interest therein, if any.
F2: These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023).